Skip to main content

RT @JulianSegan: Denosumab in erosive hand OA. 12-weekly dosing, primary end-point at 24 weeks. @RheumNow #ACR22 #LateB

Nov 14, 2022 10:06 am
Social Author Name
Julian Segan
Tweet Content
Denosumab in erosive hand OA. 12-weekly dosing, primary end-point at 24 weeks. @RheumNow #ACR22 #LateBreaking
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×